1   
 
 
 
 
 
 
 
 
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute 
Charcot Neuroarthropathy   
 
 
[STUDY_ID_REMOVED]  
9/30/19  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Table of Contents  
               
1. INTRODUCTION                                                        
 1.1 Background                        
 1.2 Potential Pharmacotherapy                      
 1.3 Prolia Description  
 1.4 Prolia Indications  and Adverse Effects  
2. STUDY DESIGN  
 2.1 Study Objective  
    2.1.1 Use of Historical Controls  
 2.2 Treatment Groups  
 2.3 Study Duration  
 2.4 Study Endpoints  
    2.4.1 Primary Endpoints  
    2.4.2 Secondary Endpoints  
    2.4.3 Exploratory Endpoints  
 2.5 Measurement Methods  
3. POTENTIAL ADVERSE EVENTS AND BENEFITS  
 3.1 Adverse effects of Prolia  
 3.2 Benefits of Study  
4. SUBJECT SELECTION  
 4.1 Informed Consent/Screening Visit  
    4.1.1 Medical History Screening  
    4.1.2 Physical Assessment Screening  
       4.1.2.A Test for Acute Charcot Neuroarthropathy  
       4.1.2.B Test for Peripheral Neuropathy  
       4.1.2.C Preliminary Lab Tests  
       4.1.2.D Dental Health Screening  
 4.2 Inclusion Criteria  
 4.3 Exclusion Criteria  
 4.4 Method of Subject Assignmen t to Treatment Groups  
5. STUDY PROCEDURES  
 5.1 Surveys  
 5.2 Initial Visit  
    5.2.1 Enrollment  
    5.2.2 Medical History  
    5.2.3 Physical Examination  
    5.2.4 Laboratory Procedures  
    5.2.5 Radiographic Procedures  
    5.2.6 Adverse Events Pre -screen  
    5.2.7 Treatment  
 5.3 Follow -up Visits  
    5.3.1 Patient Information  
    5.3.2 Physical Examination  
3     5.3.3 Laboratory Procedures  
    5.3.4 Radiographic Procedures  
    5.3.5 Adverse Events  
    5.3.6 Treatment  
 5.4 Total Contact Casting Methods  
    5.4.1 Application of Total Contact Cast  
    5.4.2 Removal of Total Contact Cast  
 5.5 Administration of Prolia Methods  
    5.5.1 Storage and Handling of Prolia  
    5.5.2 Subject Education  
    5.5.3 Administration of Prolia  
    5.6 Flow  sheet Summarizing Office Visits  
    5.7 Subject compensation  
6. SUBJECT COMPLETION OR DISCONTINUATION  
 6.1 Subject Completion  
 6.2 Subject Discontinuation  
7. SAFETY ASSESSMENT  
 7.1 Safety Evaluation  
 7.2 Adverse Events  
    7.2.1 Adverse Events Causality  
 7.3 Se rious Adverse Events  
 7.4 Documentation and Reporting of Adverse Events  
 7.5 Procedure for Adverse Event Reporting  
8. SUBJECT PROTECTION REQUIREMENTS  
9. REGULATORY REQUIREMENTS  
10. RESPONSIBILITIES OF THE INVESTIGATORS  
 10.1 Obtaining Subject Informed Con sent 
 10.2 Subject Confidentiality  
 10.3 Access to Data/Documents  
 10.4 Product Delivery, Storage, and Returns  
 10.5 Data Handling  
10.6 Data A nalysis  
 
 
 
 
 
 
 
 
 
 
 
 
4  
1 INTRODUCTION  
 
1.1 Background  
Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled 
diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the 
foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences 
frequently le ad to below -knee amputation of the affected limb. The literature estimates that CN 
affects 0.08% of diabetics. However, the prevalence can be as high as 13% among high -risk 
diabetic patients (1). Patients with CN are reported to have a significant decrease d ability to 
perform activities of daily living and experience a lower quality of life compared to diabetics 
without pedal complications ( 2, 3). The disease also has a significant impact on health -care 
costs, with CN accounting for an estimated $5.4 millio n in California in -patient health -care costs 
annually between 2008 and 2012 (4).  
 
CN is characterized by a sequence of inflammation and osseous degradation. The disease 
process begins in the acute phase, characterized by severe inflammation. Patients suff ering 
from concomitant neuropathy will generally continue to ambulate on the affected limb. This 
exacerbates the inflammatory process and creates a devastating inflammatory cascade, leading 
to severe osseous destruction and joint dislocation. The inflammat ory cascade will eventually 
regress naturally, causing the remodeled bone to consolidate in a malalignment . This leads to a 
characteristic rocker bottom deformity. This resultant deformity is often nonfunctional, and, 
depending on the severity, may require  reconstructive surgery or amputation below the knee (5 -
7). 
 
Recent breakthroughs in identifying the etiology of CN have clarified the specific influence of a 
variety of inflammatory molecules and cytokines. In the osteolytic acute phase of CN, there is 
also an increased level of tumor necrosis factor alpha (TNF -ùõº), which may be causing an 
inflammatory cascade of events (8). (TNF -ùõº) has been found to increase expression of the 
receptor activator of nuclear factor kappa -B ligand (RANKL), leading to activation of the nuclear 
factor kappa -light-chain -enhancer of activated B cells (NF -kB) (9, 10). This ultimately leads to 
osteoclastogene sis and bone turnover (11). The increase in osteoclast activity, combined with 
persistent ambulation, leads to further osseous fracture and bone weakening (12, 13). These 
fractures further stimulate the inflammatory process and exacerbate the devastating c ycle (14).  
 
The current gold standard for treatment of acute CN is immediate non -weightbearing in a total 
contact cast (TCC) (15).  This stage of treatment requires frequent changing of the TCC, and 
can last for up to 6 months (16). Resolution of skin temp erature gradient clinically defines the 
end of the acute phase. Specifically, the acute phase is considered resolved  when the skin 
temperature of the affected foot reaches + 2 degrees Celsius of the contralateral foot (7). Once 
the acute phase concludes, t he patient is transitioned to weightbearing status in a patient -
specific molded Charcot Restraint Orthotic Walker (CROW).  
 
 
5  
1.2 Potential Pharmacotherapy  
Studies have investigated the use of bisphosphonates in treating the inflammatory stage of CN, 
but these studies failed to demonstrate a clear clinical benefit (17, 18). TNF -alpha inhibitors, 
calcitonin, and human parathyroid hormone have also been propose d (19). However, none of 
these medications have been formally investigated or FDA approved for the treatment of acute 
CN.  
A recent systematic review reinforced the opinion that anti -RANKL agents may represent a 
breakthrough in the treatment of acute CN, c oncluding, given the role of the R ANK/R ANKL 
pathway in CN pathophysiology, RANKL inhibition may represent an effective treatment for 
acute CN  (20). Nonetheless, to date, there are no studies on the use of anti -RANKL agents for 
this disease.   
 
1.3 Prolia D escription  
Prolia (denosumab), a potent RANKL inhibitor, has been observed to reduce bone turnover and 
increase bone mineral density in both female and male osteoporotic patients. 60 mg Prolia 
delivered once subcutaneously every 6 months has been shown to be safe to use and is able to 
reduce fracture risk in osteoporotic patients (21 -25). Prolia , when compared to alendronate (a 
bisphosphonate) has  been shown to be more effective at increasing bone mineral density with 
less adverse events in osteoporotic pat ients (26, 27).  
 
Inflammatory cytokines stimulate the production of RANKL, which leads to the maturation of 
osteoclast progenitors. By inhibiting the binding of RANKL to its receptor, denosumab inhibits 
osteoclast formation, function and survival, which in  turn, may arrest the bony destruction that 
characterizes CN thus making Prolia a  major candidate for the treatment of acute CN.  
 
1.4 Prolia Indications  and Adverse Effects  
Prolia is a RANK ligand (RANKL) inhibitor indicated for:  
‚Ä¢ Treatment of postmenopaus al women with osteoporosis at high risk for  
fracture   
‚Ä¢ Treatment to increase bone mass in men with osteoporosis at high risk  
for fracture  
‚Ä¢ Treatment to increase bone mass in men at high risk for fracture  
receiving androgen deprivation therapy for nonmetastat ic prostate cancer  
‚Ä¢ Treatment to increase bone mass in women at high risk for fracture  
receiving adjuvant aromatase inhibitor therapy for breast cancer  
 
 Contraindications:  
‚Ä¢ Hypocalcemia   
‚Ä¢ Pregnancy  
‚Ä¢ Known hypersensitivity to Prolia   
 
‚Ä¢ Warnings and precautions:Same Active Ingredient: Patients receiving Prolia should not 
receive  
6 XGEVA¬Æ  
‚Ä¢ Increased risk of multiple vertebral fractures following Prolia discontinuation  
‚Ä¢ Hypersensitivity including anaphylactic reactions may occur.  
Discontinue permanently if a clinically significant reaction occurs  
‚Ä¢ Hypocalcemia: Must be corrected before initiating Prolia. May worsen,  
especially in patients with renal impairment. Adequately supplement  
patients with calcium and vitamin D.  In patients p re-disposed to hypocalcemia and disturbances of 
mineral metabolism, clinical monitoring of calcium and mineral levels (phosphorus and 
magnesium) is highly recommended within 14 days of Prolia injection.  
‚Ä¢ Osteonecrosis of the jaw: Has been reported with Prol ia. Monitor for  
symptoms  
‚Ä¢ Atypical femoral fractures: Have been reported. Evaluate patients with  
thigh or groin pain to rule out a femoral fracture  
‚Ä¢ Serious infections including skin infections: May occur, including those  
leading to hospitalization. Advise p atients to seek prompt medical  
attention if they develop signs or symptoms of infection, including  
cellulitis  
‚Ä¢ Dermatologic reactions: Dermatitis, rashes, and eczema have been  
reported. Consider discontinuing Prolia if severe symptoms develop  
‚Ä¢ Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe  
symptoms develop  
‚Ä¢ Suppression of bone turnover: Significant suppression has been  
demonstrated. Monitor for consequences of bone oversuppression  
  
 Adverse Reactions:  
‚Ä¢ Postmenopausal osteoporosis: Most common adverse reactions (> 5%  
and more common than placebo) were: back pain, pain in extremity,  
hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis  
has been reported in clinical trials  
‚Ä¢ Male Osteoporosis: Most common adverse reactio ns (> 5% and more  
common than placebo) were: back pain, arthralgia, and nasopharyngitis  
‚Ä¢ Bone loss due to hormone ablation for cancer: Most common adverse  
reactions (‚â• 10% and more common than placebo) were: arthralgia and  
back pain. Pain in extremity and m usculoskeletal pain have also been  
reported in clinical trials  
 
 
 
 
 
 
 
 
 
7  
2 STUDY DESIGN  
 
2.1 Study Objective  
The primary objective of this study is to assess the safety of denosumab 60 mg, in conjunction with 
a TCC, as a treatment for acute CN. This pilot study will inform feasibility of an appropriately 
designed randomized, controlled study . This study will be a prospective,  single -arm, open -label , 
Phase 1  trial. 
 
Safety will be assessed by reported and observed adverse events . These will be recorded  at each 
follow -up visit. Objectively, efficacy will be defined clinically as the reduction in foot temperatures 
compared to a baseline value.  
 
 The clinical importance of foot temperatures in the context of acute Charcot neuroarthropathy has 
been establis hed in the medical literature. Skin temperature was formally described as a measure 
of acute phase activity in 1972 (28). Subsequent studies provided further validation, identifying the 
correlation of skin temperature with disease activity ( 29, 33, 34). Cl inical studies , including those  
evaluating pharmaceutical interventions , have predominantly relied upon skin temperature in 
defining the resolution of the acute phase ( 17-18, 28-35).  
 
Lab values will be used as markers of bone turnover and inflammation.  These will be measured at 
the initial and ea ch follow -up visit. Bone specific alkaline phosphatase (BS AP) is a marker of bone 
turnover .  While a marker of bone formation , BSAP has been shown to be elevated in acute 
Charcot neuroarthropathy reflecting ongoing bone turnover and remodeling. Subjectively efficacy 
will be determined by recording symptom score on an 100 -point Visual Analog Scale (VAS, 100mm 
scale ). The surveys will be taken at the initial visit and at each follow -up visit. A study schema is 
provided in section 5.6. All enrolled patients will be receiving both pharmaceutical  treatment (Prolia) 
and standard of care.  
  
      As this study is a pilot study and there fore explicitly underpowered, a power analysis was not     
      performed. Statistical analysis will consist of descriptive statistics of the subject demographics,  
      mean temperature differential of the subjects stratified by length of follow -up, mea n BSAP levels  
      stratified by length of follow -up, mean time until normalization of skin temperature gradient   
      (within 2 degrees Celsius) , and mean change in VAS stratified by length of follow -up. Graphical  
      representations of temperature  differential and BSAP by length of follow -up among subjects will be  
      presented.   
 
2.1.1 Use of Historical C ontrols  
      The future, adequately -powered study, which this pilot serves as a precursor to, will focus on  
      efficacy rather than safety as the primary endpoint. Data from this p ilot study, in combination with  
study dat a from the existing literature will be  used to ensure  the future study will be adequately 
powered.  The rationale for using a historical control is to allocate more novel resources to the 
patients enrolled in this study. This will also help increase the power of the study as well as reduce 
type 1 error.  Data from the following studies which will be included for this purpose is listed below:  
8  
Bem R, et al. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a 
randomized controlled trial. Diabetes Care. 2006 Jun;29(6):1 392-4. 
A 2006 study by Bem et al investigating the use of intranasal calcitonin included 16 control patients  
affected by Charcot neuroarthropathy . Initial skin temperature differential between the affected and 
non-affected limb was 3.6 +/ - 0.8¬∞ C in the co ntrol group. At 3 months, the skin differential between 
the affected and non -affected limb was 1.5 + 0.5¬∞C which is a 2.1¬∞C   improvement . Skin 
temperature difference was also calculated at 1 , 2 and 6 months after baseline. All patients were 
treated with off -loading by removabl e contact cast or cast walker.  
 
Pitocco D, et al. Six -month treatment with alendronate in acute Charcot neuroarthropathy: a 
randomized controlled trial. Diabetes Care. 2005 May;28(5):1214 -5.  
 
A 2005 study by Pitocco et al incl uded 9 control patients. Initial skin temperature differential was 3.4 
+/- 1.2¬∞ C in the control group and 3.6 +/ - 1.1¬∞ C in the treatment group. At 6 months, there was a 
1.5¬∞ C improvement in the control group  and a 1.7¬∞ C improvement in the treatment gro up 
(temperature differential of 1.9¬∞ C in each group) . There was no difference between the temperature 
differential between control and treatment groups at 6 months. Patients were treated with a total 
contact cast for the first 2 months and then a pneumati c walker for 4 months , though the treatment 
group was also administered alendronate.  
 
Jude EB1, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double -blind 
randomised controlled trial. Diabetologia. 2001 Nov;44(11):2032 -7. 
A 2001 st udy by Jude et al included 18 control patients. Initial skin temperature differential was 3.3¬∞ 
+/- 1.4¬∞ C in the control group. After 4 weeks, the skin temperature differential was improved by 1.4 
+/- 0.7¬∞ C in the control group , with an overall reduction in skin temperature to 1.9¬∞ C  between the 
affected and non -affected limb . Skin temperature gradient among the control was also portrayed 
graphically at 2, 4, 6, 8, 10, 12, 24, 36, and 52 weeks. Control patients were offloaded using either a 
scotch cast boo t, pneumatic walker, or total contact cast.  
 
Armstrong DG, Lavery LA. Monitoring healing of acute Charcot's arthropathy with infrared dermal 
thermometry. J Rehabil Res Dev. 1997 Jul;34(3):317 -21. 
A 1997 study by Armstrong and Lavery fol lowed 39 acute Char cot patients, without an intervention 
group . Patients were offloaded using either total contact casts or removable cast walkers. Mean 
temperature differential was reported on  a monthly basis for 12 months.  While  a graphical 
representation of the monthly me an temperature difference is provided  in the study  (using point 
estimates), explicit numerical values are not provided.   
 
Armstrong DG1, Lavery LA, Liswood PJ, Todd WF, Tredwell  JA. Infrared dermal thermometry for 
the high -risk diabetic foot. Phys Ther. 1997 Feb;77(2):169 -75; discussion 176 -7. 
This 1997 study, also led by Armstrong, foll owed 21 acute Charcot patients. The study compared 
the patients with Charcot against two separ ate groups: an asymptomatic neuropathy group, and a 
neuropathic ulcer group. The study reported an initial temperature difference of 8.3¬∞F (90.4¬∞F 
9 versus 82.1¬∞F). The only further temperature gradient was reported as 0.04¬∞F at 12 months, though 
the exact  background temperature values were not reported.  
 
 
Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR. The natural history of acute 
Charcot's arthropathy in a diabetic foot specialty clinic. J Am Podiatr Med Assoc. 1997 
Jun;87(6):272 -8. 
Game FL, et al. Audit of acute Charcot's disease in the UK: the CDUK study. Diabetologia. 2012 
Jan;55(1):32 -5. 
Two additional studies reported time -to-resolution of the acute phase, though did not report 
temperature gradient after baseline. Time -to-resolution data is c linically useful, providing an 
estimate of the length of the acute phase period. As a marker of disease activity, however, skin 
temperature gradient is of potentially greater use. Time -to-resolution data only reflects the end of 
the acute phase period; thi s data does not indicate if the clinical response, for example, occurred 
mostly during certain time intervals or was more gradual in nature. Skin temperature gradient, 
reported at defined intervals, can provide a more complete representation of disease act ivity. This 
information can be used to correlate the clinical response to external events, such as the 
administration of medication or a change  in off -loading modalities.   
 
A study by A rmstrong  et al in 1997 followed 55 patients without an intervention gro up, with an 
average initial temperature gradient of 5.1 +/ - 1.4¬∞ C. Patients were non -weight -bearing and 
immobilized in serial casts for an average acute phase period of 18.5 +/ - 10.6 weeks. An 
observational study by Game et al in 2012 included a large vol ume of patients, though the study 
was uncontrolled and affected by a range of design concerns. Off -loading consisted initially of a 
non-removable device in 35.4% of cases and with a removable device in 50% of cases. The median 
time-to-resolution of the 121  patients who were treated without bisphosphonates was 10 months 
(range: 2 -29 months).  
 
 
While skin temperature gradients serve as the secondary efficacy endpoints at 6 and 12 months, 
the skin temperature gradients will be calculated at every follow -up ap pointment.  This data in 
comparison with historic al controls will be utilized in future  power analyses to determine sample 
size.  
 
2.2 Treatment Group   
Subjects will be assigned to a single treatment group and  will receive offloading with a TCC and a  
60 mg SC dose of Prolia . The TCC offloading device will be identica l for all subjects. As the goal will 
be for 6 subjects to complete the trial, 7 subjects will be enrolled to allow dropout of 14.3% (1 
subject) . The historical controls may have a potentia l source of variation given the differences in 
offloading devices, but the variability is minimal and should not be a major source of confounding.  
 
2.3 Study Duration  
Each su bject will participate in this P hase 1 trial  for a total of 1 year. There will be a screening visit 
with podiatry,  2 additional screenings with physical therapy and dentistry respectively , and biweekly 
10 follow -ups thereafter with podiatry and either endocrinology or rheumatology until the 3rd month. 
The subject will also return for 6th, 9th and 12th month follow -ups where they will be m onitored for 
adverse events; pain will be assessed using the  Visual Analog Scale, scored out of 100 . Office 
visits will be jointly conducted by a podiatrist and , alternatingly,  either a rheumatologist (Dr. 
Emmanuel Katsaros) or an endocrinologist (Dr. Airani Sathananthan) . The evaluation by the 
rheumatologist and endocrinologist will focus on vigilant monitoring for adverse events from 
treatment.  
 
2.4 Study Endpoints  
 
2.4.1 Primary Endpoints  - Safety  
1. Subject incidence of adverse events and changes in lab values.  
 
2.4.2 Secondary Endpoints  - Efficacy  
1. Change in skin temperature difference  in degrees Celsius  between  the affected  and non -affected  
limb at 6 months and 12 months.  For each individual, the following difference will be calculated:  
Temperature (affected limb,  ¬∞C) minus temperature (unaffected limb, ¬∞C) at month 6.  
Temperature (affected limb, ¬∞C) minus temperature (unaffected limb, ¬∞C) a t month 12.  
There are therefore effectively two secondary efficacy endpoints.  
 
 
 
2.4.3 Exploratory Endpoints  
      1. Change from baseline Visual Analog Scale (VAS, 100mm scale) survey scores at 6 months and  
      12 months.  
 
2.5 Measurement Methods  
At each study visit, the treating podiatrist will visually and physically assess patients. Skin temperature 
will be recorded using an infrared thermometer.  The same infrared thermometer will be used at each 
patient encounter to maintain consistency.   Laborat ory values will be obtained at every visit.  See 
Section 4.1.2.C for list of tests. The Visual Analog Scale  pain survey  will be administered at every visit 
to subjectively measure patient pain .  
 
 
 
 
 
 
 
 
 
 
 
 
11 3 POTENTIAL RISKS AND BENEFITS  
3.1 Adverse effects of Prolia   
See Section 1.4. Subjects will be advised to contact study coordinators if they notice signs of any of the 
adverse effects  mentioned in Section 1.4 . Comprehensive dental will be provided prior to enrollment in 
the study. Subjects will be  advised to maintain proper oral hygiene during the study. If subjects require 
dental care following the dental screening, they will be advised to inform their dentist that they are 
receiving Prolia and should therefore avoid invasive dental procedures dur ing treatment  (due to the risk 
of osteo necrosis of the jaw ).  
 
In consideration of the potential musculoskeletal risks of Prolia, including muscle weakness, 
comprehensive physical therapy screenings will also be coordinated. Physical therapy evaluations wi ll 
occur prior to enrollment, will subsequent appointments determined based on the needs of the 
individual subject.  
 
3.2 Contraindications to Prolia administration  
‚óè See section 1.4  
 
3.3 Benefits of Study  
Because recent research supports the role of inflammatory cytokines in the pathogenesis of the 
disease, it is important to explore treatment options for the disease which can decrease inflammation 
and halt the disease process. By inhibiting RANK/ RANKL  pathway in CN pathophysiology, it is 
hypothesized that the acute phase of the disease will be arrested. This can prevent the development of 
debilitating deformities and the possible consequences therein, including medial arch collapse, a 
rocker -bottom foot, bo ny deformity, ulceration, infection, and eventual amputation.  
 
It is believed that the potential benefits of this study outweigh the potential risks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 4 SUBJECT SELECTION  
Prior to screening for eligibility for the study, an informed consen t must be obtained. Eligibility will be 
determined by a set of inclusion and exclusion criteria  outlined in Sections 4.2 and 4.3 . 
 
4.1 Informed Consent/Screening Visit  
Subjects will complete a written informed consent prior to screening for eligibility. This will be 
administered by the investigators at the study site in the patient‚Äôs preferred language (English or 
Spanish). The informed consent must be signed and dated. Each subject will be assigned a number in 
ascending order beginning from 01. A screening log of all the subjects will be obtained for each written 
informed consent. The screening log includes: screening number, first and last name, age, gender, 
eligibility  status or reason for ineligibility.  This information will be stored in a locked security box , and 
kept in a locked cabinet at the Patient Care Center. This will be accessible by Dr. David Shofler and 
specifically designated study personnel.  
 
4.1.1 Medica l History Screening  
Subject eligibility will be determined by the inclusion/exclusion criteria. Record if the subject does or 
does not meet the criteria.  
1. Record date of visit, subject enrollment number, and subject initials  
2. Verify subject eligibility  based on inclusion and exclusion criteria. Adherence to criteria will be 
noted.  
3. Record subject demographics, including date of birth, gender, race, and weight, and if there were 
any treatments attempted prior to enrollment.  
 
4.1.2 Physical Assessment S creening  
Subject eligibility will be determined by the inclusion and exclusion criteria. Subject adherence to 
inclusion or exclusion criteria will be recorded.  
 
4.1.2.A Criteria for Diagnosis of Acute Charcot Neuroarthropathy  
Subjects must be diagnosed wi th acute CN. The subject must have been diagnosed with acute 
CN within 1 month. Any prior treatments will be noted on the screening log. At least two of the 
clinical criteria must be met , one of which must include elevated limb temperature . Radiographic 
staging will be recorded as well.  
Clinical criteria : 
‚óè Erythema and/or  
‚óè Edema and/or  
‚óè Heat: Temperature gradient difference of > 2 degrees C elsius of affected limb to non -
affected limb, with the  affected limb having the higher temperature  
 
Radiographic criteria : 
‚óè Modified Eichenholtz Stage 0: Radiographs are negative or  
‚óè Modified Eichenholtz  Stage 1: Subchondral bone fragmentation, periarticular fracture with 
or without joint subluxation/dislocation  
 
1. The physician will visually assess for the presence of erythema and edema.  
13 2. The temperature gradient between the affected and non -affected limb will be assessed with 
an infrared thermometer.  
3. X-rays will be taken of the foot in AP, lateral, and oblique vie ws.  
4. Ankle x -rays will be taken in AP, lateral , and mortise  views.  
 
4.1.2.B Criteria for Diagnosis of Peripheral Neuropathy  
‚óè Patients must be either previously diagnosed with neuropathy or meet the criteria of the 
following screening exams for neuropathy  
‚óã Semmes Weinstein Monofilament Test (SWMF) with loss of protective sensation 
in > 4 of 10 locations of the affected limb OR  
‚óã Vibration perception threshold biothesiometer mean read ing of > 25 mV to the 
great toe  
-  If a previous diagnosis of neuropathy is use d to meet this criteria, a physician‚Äôs record 
will be required and will be incorporated into the patient‚Äôs file.  
 
4.1.2.C Preliminary Lab Tests  (Initial Visit)  
‚óè Pregnancy test (if appropriate)  
‚óè CBC with differential  
‚óè CRP  
‚óè ESR 
‚óè Chem -7 panel  
‚óè (Sodium, Potassium, Chloride, Bicarbonate, BUN, Creatinine, Glucose)  
‚óè Liver function tests  
‚óè Calcium  
‚óè HbA1c  
‚óè Fasting blood glucose  
‚óè Bone specific alkaline phosphatase  (BSAP)  
 
4.1.2.D Dental Health Screening  
Subject‚Äôs dental health will be evaluated  
‚óè Consultation with Dr.  Diana Folmsbee, DMD  
‚óè Radiographic studies  
‚óã Panoramic Radiograph  
‚óã 4 Bitewing Radiographs  
‚óã 2 Periapical Radiographs ‚Äì on a case -by-case basis  
 
4.1.3.E  Physical Therapy Screening  
  Subject‚Äô s physical strength  will be evaluated , and mobility protocol completed  
‚Ä¢ Consultation with Dr. Lindsey Liggan, PT, DPT  
 
4.2 Inclusion Criteria  
Subjects must meet the following inclusion criteria in order to qualify for enrollment:  
1. Men or women > 30 years old  
2. Subject is able and willing to comply with study proc edures, and is able to give signed and dated 
consent  
14 3. Subject meets criteria for diagnosis of Diabetes Mellitus Type 1 or 2, active Charcot 
neuroarthropathy, and peripheral neuropathy  
4. Subjects with serum calcium or albumin -adjusted serum calcium ‚â•2.0 mmol/L (8.0mg/dL)  
 
To recruit potential subjects, podiatric offices local to a 15 miles radius will be informed of the study. 
The primary investigator will reach out to the podiatric offices directly, and a flyer advertisement will be 
distributed. Subject s will be enrolled at the Foot and Ankle Clinic of the WesternU Patient Care Center. 
The period of enrollment for the study will be up to 2 years. For subjects that meet the inclusion criteria, 
a written and oral consent will be collected. All office visit s will occur at the WesternU Patient Care 
Center.  
 
For Women of Child bearing potential:  
 Must agree to practice abstinence (not have sex) or must agree to use a highly effective method of 
birth control during treatment with denosumab and for an additional 5 months after the last dose of 
denosumab.  Postmenopausal women are those who fit into one of the following categories:  
                ‚àí     Age ‚â• 55 years, with cessation of menses for 12 or more months.  
                ‚àí     Age < 55 years, b ut no spontaneous menses for at least 2 years.  
                ‚àí     Age < 55 years and spontaneous menses within the past 1 year,  but currently 
amenorrheic (for example, spontaneous or secondary to hysterectomy), AND with documented 
postmenopausal gonadot ropin levels (luteinizing hormone and follicle -stimulating hormone levels > 40 
IU/L) or postme nopausal estradiol levels (< 5 n g/dL) or according to the definition of "postmenopausal 
range" for the laboratory involved.  
                ‚àí     Underwent a bil ateral oophorectomy.  
 
 Highly effective methods of birth control include:  
‚Ä¢ Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or skin 
patch)  
‚Ä¢ Single hormonal methods (progesterone) to release the egg from the ovary (pills, 
shots/injec tions, or implants placed under the skin by a healthcare provider)  
‚Ä¢ Intrauterine device (IUD)  
‚Ä¢ Intrauterine hormonal -releasing system (IUS)  
‚Ä¢ Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion)  
‚Ä¢ Your male partner has had a vasectomy and tes ting shows there is no sperm in the semen  
 
 
4.3 Exclusion Criteria  
Subjects will not be enrolled in the study if any of the following criteria are met  
 1. Unable to provide signed and dated consent . 
 2. Charcot neuroarthropathy of the ipsilateral lower ex tremity , diagnosed over 1 month prior . 
3. Prior foot or ankle surgery of the ipsilateral lower extremity . 
4. Prior amputation at any level of either lower extremity.  
5. Prior foot or ankle fracture of the ipsilateral lower extremity unrelated to the current acute CN  
episode . 
 6. Currently has any of the following:  
15 a. Infection  
b. Foot u lceration  
c. Hypocalcemia  
d. Creatinine clearance less than 30 mL/min or on dialysi s 
e. Pre-existing disturbance of mineral metabolism (e.g., hypoparathyroidism  unstable on 
therapy , thyroid or parathyroid surgery, vitamin D deficiency, malabsorption syndromes, 
excision of small intestine , history of diseases affecting bone metabolism ) that has not been 
effectively corrected or treated . 
7. Have undergone revascularization procedures  of the lower extremities.  
8. Female subjects who are pregnant or planning to breastfeed should not participate in this study.  
9. Determined to have poor oral h ygiene after dental screening or are at increased risk for 
developing osteonecrosis of the jaw . 
10. History of osteonecrosis of the jaw.  
11. History of tooth extraction or other dental surgery within the prior 6 months.  
12. Invasive dental work planned in the next 2 years.  
13. Have a known hypersensitivity to Prolia.  
14. Known use of a bone active medication within the 6 months prior to enrollment.  
15. Liver disease, defined as AST > 2.0x ULN, ALT > 2.0x ULN, TBL > 1.5x ULN.   
16. Malignancy within the last  5 years (except cervical carcinoma in situ or basal cell carcinoma)  
 
 
4.4 Method of Subject Assignment to Treatment Group  
Subjects will be enrolled into the study after verification of eligibility according to the inclusion and 
exclusion criteria. Written  informed consent will also be obtained from subjects. Each subject will 
receive a unique  enrollment number. This will be a n open label Phase 1 trial . Both the investigators and 
the subjects will be aware of the treatment the subjects will be receiving. There will be only one 
treatment group.  The length of time considered acceptable between screening tests and study 
enrollment will be 30 days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 5 STUDY PROCEDURES  
 
5.1 Surveys  
Surveys will be performed during screening visits.  
5.2 Initial Visit  
 
5.2.1 Enrollment   
Refer to section 4  
 
5.2.2 Medical History  
1. Record date of visit, subject enrollment number, and subject initials  
2. Verify subject eligibility based on inclusion and exclusion criteria. Adherence to criteria will be 
noted.  
3. Record subject demographics, including date of birth, gender, race  
4. Past medical his tory will be recorded in detail, including a careful screening relevant to future 
potential adverse events.  
5. Subject will complete a VAS survey . The 100-point  Visual Analog Scale (VAS, 100mm scale ) 
pain survey will be administered by the podiatrist overseeing care of the subjects at the initial and 
every follow -up visit.  
 
 
5.2.3 Physical Examination   
Refer to section 4.1.2  
‚óè Evaluate change in inflammation  
‚óã Describe location and extent of erythema  
‚óã Grade edema (mil d, moderate, severe)  
‚óã Measure temperature gradient difference between affected and non -affected limb 
using infrared thermometer  
‚óè Test for peripheral neuropathy  
 
5.2.4 Laboratory Procedures  
The following lab results will be obtained  
‚óè Pregnancy test (if appropriate)  
‚óè CBC with differential  
‚óè CRP  
‚óè ESR 
‚óè Chem -7 panel  
‚óè (Sodium, Potassium, Chloride, Bicarbonate, BUN, Creatinine, Glucose)  
‚óè Liver function tests  
‚óè Serum Calcium  
‚óè Serum Phosphorus  
‚óè HbA1c  
‚óè Fasting blood glucose  
‚óè Bone specific alkaline phosphatase  (BSAP)  
17   
5.2.5 R adiographic Procedures  
‚óè Foot x -rays 3 views   
‚óè Ankle x -rays 3 views  
 
5.2.6 Adverse Events Pre -screen  
The medical history  recorded during the initial visit will be carefully performed in order to evaluate the 
significance of adverse events in the future. Both a rheumatologist and  endocrinologist will be present 
at every visit, alongside a podiatrist, to monitor for adverse e vents .  
 
5.2.7 Treatment  
   5.2.7.A Administration of Prolia Solution  
All subjects will receive Prolia at the second  visit. Refer to section 5.3.6.A and section 5.5. This will 
occur no later than 30 days after screening.  
 
   5.2.7.B Administration of Total Contact Cast  
All subjects will receive a total contact cast (TCC) at the initial visit. Refer to section 5.4.  
 
5.2.7.C  Scheduling of Screening visits  
Physical therapy and dental follow -up visits will be scheduled durin g the initial visit.  
 
5.3 Follow -up Visits  
 
5.3.1 Patient Information  
1. Record date of visit, subject enrollment number, and subject initials . 
2. Subject will complete  a VAS survey . 
 
5.3.2 Physical Examination   
Refer to section 4.1.2  for more detail.  
‚óè Evaluate change in inflammation  
‚óã Describe location and extent of erythema  
‚óã Grade edema (mild, moderate, severe)  
‚óã Measure  skin temperature of the affected limb and the non-affected limb using  an 
infrared thermometer  
‚óè Test for peripheral neuropathy  
 
5.3.3 Laboratory Procedures  
‚óè CBC  with differential  
‚óè Chem -7 panel  
‚óè Serum Calcium  
‚óè Serum Phosphorus  
‚óè HbA1c  (if previous test was in excess of 3 months prior)  
‚óè Fasting blood glucose  
‚óè Bone specific alkaline phosphatase (BSAP)  
18   
5.3.4 Radiograph ic Procedures  
‚óè Radiographs of the foot and ankle will be ordered on an as -needed basis  
‚óè Foot x -rays 3 views  
‚óè Ankle x -rays 3  views  
 
5.3.5 Adverse Events  
‚óè Both the  rheumatologist  and endocrinologist will be present at every visit, alongside the 
podiatrist, to monitor for adverse events  
 
5.3.6 Treatment  
5.3.6.A Administration of Prolia Solution  
All subj ects will receive one injection of Prolia, occurring at the second visit (the first follow -up visit).  
Refer to section 5.5. This will occur no later than 30 days after screening.  
 
   5.3.6.B  Administration of Total Contact Cast  
All subjects will receive a total contact cast at each follow -up visit. Refer to section 5.4.  
 
5.4 Total Conta ct Casting Methods   
A total contact cast will be applied to all participants at all visits until the active phase of CN has 
subsided. All subjects will be non -weightbearing while wearing the total contact cast, with the 
assistance of a wheelchair , knee -walker, or crutches (weight -bearing to non -affected limb) while 
wearing the total contact cast. The ability to maintain non -weightbearing status using crutches will be 
verified, and if there is any doubt a wheelchair or knee -scooter will be utilized instead.  
 
5.4.1 Application of Total Contact Cast  
The podiatrist will be directly involved in application of the total contact cast. Application should be 
quick and smooth to avoid weakening of the cast. An assistant will be involved with cast application to 
ensur e proper positioning of the affected lower limb.  
 
Casting will be applied with the patient in the supine position. The affected limb will be covered with a 
light dressing if applicable, and  skin preparation will be performed as needed. A stocking will be used 
as a first layer, extending from the toes to the tibial tuberosity. Cast-padding will be applied to the lower 
extremity, including bony prominences of the limb. Fiberglass material will then be applied from the toes 
to the tibial tuberosity.  
 
5.4.2 Removal of Total Contact Cast  
The podiatrist will b e directly involved in removal of the total contact cast. A cast saw will be used to 
remove the cast. Proper technique will be used to ensure safe removal.  
 
5.5 Administration of Prolia Methods  
All subjects will receive  a subcutaneous  injection of Prolia at the second  visit (the first follow -up visit) . 
Subjects will be given Calcium and Vitamin D supplementations (‚â•1000 mg elemental calcium and 
‚â•800 IU vitamin D) during denosumab treatment.  
19  
5.5.1 Storage and Handling of Prolia  
Prolia is supplied in a sin gle-use prefilled syringe with a safety guard (60 mg/1 mL in a single -use 
prefilled syringe 1 per carton NDC 55513 -710-01). Prolia is stored in a refrigerator at 2¬∞C to 8¬∞C (36¬∞F 
to 46¬∞F) in the original carton. Do not freeze. Prior to administration, Prol ia may be allowed to reach 
room temperature (up to 25¬∞C/77¬∞F) in the original container. Once removed from the refrigerator, 
Prolia must not be exposed to temperatures above 25¬∞C/77¬∞F and must be used within 14 days. If not 
used within the 14 days, Prolia should be discarded. Prolia is not to be used after the expiry date 
printed on the label. Prolia is to be protected from direct light and heat, and vigorous shaking avoided.  
The pharmacist will maintain a secured log of refrigerated medications, and the re frigerator will be 
secured. The pharmacist alone will have access to the medication log and the refrigerator.  
 
5.5.2 Subject Education  
Subjects will be informed of the adverse effects of Prolia and the theoretical benefits of Prolia for the 
indication unde r investigation  (refer to sections 3.1 and 4) . 
 
5.5.2 Administration of Prolia  
60 mg of Prolia from a PFS (pre -filled syringe)  will be administered to participants during their second  
visit.  
 
Prior to administration, Prolia will be removed from the refri gerator and brought to room temperature 
(25 deg rees Celsius) in the original container.  Prolia will not be heated or warmed. Syringes  will be 
visually inspected to ensure it is a clear to pale yellow solution containing trace amounts of white 
proteinaceous particles. Syringes  will not be used if the solution is discolored or cloudy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20  
 
5.6 Flow sheet, Summarizing Office Visits  
 
 
The physical therapy screening, the dental screening, and the initial visit, are to occur within a two week 
period. The second visit, which includes injection of Prolia, is intended to occur 1 -2 weeks afterwards; 
as a limit this inte rval is not to exceed 30 days.  
5.7 Subject compensation  
Enrolled subjects will be provided a $25 stipend for every visit following the initial visit. This stipend is to 
compensate patients for associated gas and travel costs.  ‚Ä¢Complete informed consent
‚Ä¢Podiatrist & medical specialty joint visit
‚Ä¢Pregancy test (if appropiate)
‚Ä¢Blood test
‚Ä¢Radiographs
‚Ä¢Complete brief surveyInitial Visit‚Ä¢Physical therapy consultation and evaluation Screening Visit: 
Physical therapy
‚Ä¢Dental consultation
‚Ä¢Radiographic studiesScreening Visit: 
Dental screening
‚Ä¢Injection of Prolia
‚Ä¢Blood test
‚Ä¢Casting
‚Ä¢Complete brief surveySecond visit
‚Ä¢Podiatrist & medical specialty joint visit
‚Ä¢Blood test (see section 5.3.3)
‚Ä¢Casting (if necessary)
‚Ä¢Complete brief surveyFollow -up visits 
every 2 weeks
until month 3 
‚Ä¢Podiatrist and medical subspecialty office visit, focusing on adverse 
events
‚Ä¢Blood test
‚Ä¢Complete brief survey
‚Ä¢Debriefing session following the 12 -month visitFollow -up visits at 
6, 9 and 12 
months
21 6 SUBJECT  COMPLETION OR DISCONTINUATION  
 
6.1 Subject Completion  
The subject will be considered to have completed  the study a fter finishing the safety and efficacy 
evaluation at  12th month s. 
 
6.2 Subject Discontinuation  
The subject will be discontinued from the study if the subject withdraws, is withdrawn due to an adverse 
event, or is no longer able to be located. Any reason for discontinuation will be documented along with 
information about the health of the subject  at the time of withdrawal . All attempts to contact subject 
must be documented. After 3 documented failed attempts to contact  the subject , the subject will be 
considered lost to follow -up and will be discontinued.  As the design of this pilot study includes  an 
allowance of dropout of 1 subject, replacement will be sought if more than 1 subject is discontinued 
from the study (to yield a total number of subjects no less than 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 7 SAFETY ASSESSMENTS  
A safety evaluation will be conducted at every visit. Both a rheumatologist and an endocrinologist will 
be present, alongside the podiatrist, at every visit to assess and grade the presence of suspected 
adverse events.  
 
7.1 Safety Evaluation  
Safety will be  assessed by recording the nature, intensity, and duration of treatment emergent adverse 
events.  
 
7.2 Adverse Events  
An adverse event (AE) is any unintended and unfavorable sign (e.g., an abnormal laboratory finding), 
symptom or disease temporally associat ed with the use of pharmaceutical product, whether or not 
considered causally related to the product.  
Adverse events will be recorded at every visit, including both screening and follow -up visits. Recorded 
adverse events are not limited to adverse drug rea ctions (ADRs).   
  
Information collected during subject screening serves to determine if an adverse event started before or 
during the course of study and to monitor its progression throughout the course of the study. Follow -up 
evaluation and treatment wil l continue until the adverse event has resolved.  
 
7.2.2 Adverse Events Causality  
Adverse events will be assessed for causality. The event is considered related to the treatment 
intervention if there is a reasonable possibility that the treatment could ha ve contributed to the event. 
Evidence supporting the relation between treatment and adverse event can be derived from scientific 
and medical facts, observation, and professional opinion.  
 
7.3 Serious Adverse Events  
An adverse  event is considered serious (S AE) if it occurs after signing the informed consent form AND 
meets any of the following criteria:  
‚óè it results in death  
‚óè it is life threatening  
‚óè it requires hospitalization  
‚óè it results in disability or incapacity  
‚óè it jeopardizes the health of the subject, such that medical or surgical intervention is needed 
to prevent one of the aforementioned results. Generally, reconstructive surgery for Charcot 
neuroarthropathy is avoided during the acute stage. Even in the situa tion of disease 
progression, such as advanced foot dislocation or fracture, reconstructive surgical 
intervention is avoided due to risk of accelerating the disease process during this stage. 
Surgery of the lower extremity during acute CN may, however, may consist of procedures 
precipitated by infection, including: incision and drainage procedures, surgical debridement, 
and bone biopsy. Surgical intervention of this nature will be considered a serious adverse 
event.  
 
23 A life -threatening SAE is any SAE that pl aces the subject, in view of the investigator, at immediate risk 
of death from the reaction as it occurred. It does not include a reaction that, had it occurred in a more 
serious form, might have caused death.  
 
7.4 Documentation and Reporting of Adverse Ev ents 
All involved physicians will invoke the collaborative process in identify any safety concern. Team 
meetings will occur monthly, and also on as an -needed basis. All adverse events will be discussed as a 
team, and any ramifications for the remaining pat ients in the study will be discussed collaboratively as 
well. 
All adverse events will be documented. Serious adverse events will be completely reported to the study 
grant sponsor , the institutional review board (IRB), and to the University Com pliance Office,  within 24 
hours of becoming aware of the serious adverse event.  
 
7.5 Procedure for Adverse Event Reporting  (Individual Case Safety Reports)  
 
Completion of safety assessment forms : 
SAEs:  Investigators will complete safety assessment form s within 24 hours of the investigator‚Äôs first 
knowledge of the SAE. The form must be reported to the institutional review board (IRB) within  5 
calendar days.  
Non-serious AEs:  The safety assessment form must be completed within 5 calendar  days of the 
investi gator‚Äôs first knowledge of the AE.  
 
Reporting of trial product -related SUSARs:  
All suspected unexpected serious adverse reactions (SUSARs) will be reported to the Food and Drug 
Administration (FDA), Amgen as well as the institutional review board (IRB) withi n 5 calendar days. 
Cases involving pregnancy or lactation will be reported to Amgen within 10 days of awareness.  
An Annual Safety Report will be generated and reported annually. A Final Safety Report will be 
generated and reported at the conclusion of the study. Additional aggregate safety reports will be 
considered as the study progresses.  
 
Follow -up of adverse events:  
SUSARs: All SUSARs must be followed until the outcome of the event is, ‚Äúrecovered/resolved‚Äù, 
‚Äúrecovered/resolved with sequelae‚Äù, or ‚Äúfatal ‚Äù, and until all queries have been resolved. Cases of 
chronic conditions on -going at the time of death, where death is due to another AE, may be closed with 
either the outcome ‚Äúre covering/resolving‚Äù or ‚Äúnot recovered/not resolved‚Äù. If the subject has completed 
the follow -up period and is expected by the investigator to recover, the case can be closed with the 
outcome of ‚Äúrecovering/resolving‚Äù. Follow -up information should only incl ude new information and must 
be reported within 5 calendar days of the investigator‚Äôs first knowledge of the information.   
Non-serious AEs: All SUSARs must be followed until the outcome of the event is, ‚Äúrecovered/resolved‚Äù, 
‚Äúrecovered/resolved with sequelae‚Äù, or ‚Äúfatal ‚Äù, and until all queries have been resolved. Cases of 
chronic conditions on -going at the time of death, where death is due to another AE, may be closed with 
either the outcome ‚Äúrecovering/resolving‚Äù or ‚Äúnot reco vered/not resolved‚Äù. If the subject has completed 
the follow -up period and is expected by the investigator to recover, the case can be closed with the 
outcome of ‚Äúrecovering/resolving‚Äù.  
24 Queries or follow -up requests from Amgen must be responded to within 1 4 calendar days from the date 
of receipt of the request unless otherwise specified in the follow -up request.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 8 SUBJECT PROTECTION REQUIREMENTS  
 
The Principal Investigator is required to provide an Institutional Review Board (IRB)/Ethics Committee 
with necessary materials. The study cannot commence until the IRB/Ethics Committee provides written 
approval of the proposed Phase 1 trial . Appropriate r eports of progress of this study will be provided to 
the IRB/Ethics Committee in agreement with the policy established by the grant sponsor.  
 
Changes to an approved protocol may only be made by the grant sponsor with IRB authorization, 
except in instances  deemed necessary to eliminate immediate harm to the subjects or when the 
change involves only administration or logistics.  
 
Significant deviation from the protocol without appropriate approval will be regarded as a protocol 
violation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 9 REGULATORY REQUIREMENTS  
This study will be conducted in accordance with all applicable regulatory requirements, including those 
promulgated by the U.S. Food and Drug Administration, and with the principles consistent with Good 
Clinical Practice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 10 RESPONSIBILITIES OF THE INVESTIGATORS  
 
10.1 Obtaining Subject Informed Consent  
Information about the study in a language fully understandable by the eligible subject (English or 
Spanish) will be given in written and oral form by the investigator. It will be explained to subjects that 
they are free to refuse entry into the study and f ree to withdraw at any time. Written consent forms will 
be approved by the grant sponsor. The original consent form will be  placed in the subject‚Äôs study 
records and a copy will be provided to the subject.  
 
10.2 Subject Confidentiality  
The investigators will ensure that privacy of all subjects is maintained. Investigators will assure subjects 
that their personal identity and all personal medical information will be safeguarded. In all documents 
submitted to the sponsor, subjects will be iden tified by a unique identification code. All personal medical 
information will al ways be treated as confidential and in compliance with HIPAA regulations.  
 
10.3 Access to Data/Documents  
The investigators will have access to data and documents obtained from  subjects during the course of 
the study. Personal medical information may be studied for the purpose of verifying data recorded and 
subject eligibility and is only accessible to the investigators  
 
10.4 Product Delivery, Storage, and Returns  
The investiga tor is responsible for ensuring that deliveries of all material involved with the study are 
correctly received and handled. Materials will be properly labeled and safely stored. All unopened 
materials will be returned to the study grant sponsor.  
 
10.5 Data  Handling  
All data collected will be included in a report to be submitted to the study grant sponsor. The data will 
be scanned and sent through secure electronic mail (e -mail). The report will be legible.  Any errors will 
be corrected with a single line st rike-through that does not obscure the original entry and annotated 
with the investigator‚Äôs initials and current date. No data will be withheld from the report and any missing 
data will be noted with the reason for why it is missing. Frequency of case repo rt submissions to the 
grant sponsor will be decided between the  investigator and grant sponsor.  
 
10.6 Data A nalysis  
Given the small sample size , data analysis will by definition be limited to descriptive statistics. The 
mean, standard deviation, and range will be reported  for the change  of foot skin temperature compared 
to the baseline  value . Similarly, the mean, standard deviation, and range, wi ll be reported for each of 
the following dependent variables: skin gradient between the affected and nonaffected limb , bone 
specific alkaline phosphatase (BSAP), erythrocyte sedimentation rate (ESR), and 100 point Visual 
Analog Scale survey  result. This re sultant data will aid in performing a power analysis for the future 
randomized controlled trial intended . Specifically, s electing an appropriate effect size for power analysis 
calculations will be more reasonable once the data for this proposed Phase 1 tri al has been fully 
reported.  
 
28  
REFERENCES  
 
1) Donegan R, Sumpio B, Blume PA. Charcot foot and ankle with osteomyelitis. Diabet Foot Ankle. 
2013 Oct 1;4. doi: 10.3402/dfa.v4i0.21361. eCollection 2013.  
 
2) Sochocki MP, Verity S, Atherton PJ, Huntington JL, Sl oan JA, Embil JM, Trepman E. Health related 
quality of life in patients with Charcot arthropathy of the foot and ankle. Foot Ankle Surg. 2008;14(1):11 -
5. doi: 10.1016/j.fas.2007.07.003. Epub 2007 Oct 22.  
 
3) Raspovic KM, Wukich DK. Self -Reported Quality of  Life in Patients With Diabetes: A Comparison of 
Patients With and Without Charcot Neuroarthropathy. Foot Ankle Int. 2013 Dec 18.  
 
4) Shofler D, Ragothaman K, Labovitz J. The Factors Associated with Higher Costs in Inpatient 
Management of Charcot Neuroarth ropathy. Poster presented at: Diabetic Limb Salvage Conference; 
October 9, 2014; Washington D.C.  
 
5) Sinacore, Gutekunst DJ, Hastings MK, Bohnert  KL, Prior FW, Johnson JE. Neuropathic midfoot 
deformity: associations with ankle and subtalar joint motion. J Foot Ankle Res. 2013 Mar 25;6(1):11.  
 
6) Garc√≠a -√Ålvarez Y, L√°zaro -Mart√≠nez JL, Garc√≠a -Morales E, Cecilia -Matilla A, Arag√≥n -S√°nchez J, 
Carabantes -Alarc√≥n D. Morphofunctional characteristics of the foot in patients with diabetes mellitus 
and diabetic neuropathy. Diabetes Metab Syndr. 2013 Apr -Jun;7(2):78 -82.  
 
7) Rogers LC, Frykberg RG.The Charcot foot. Med Clin North Am. 2013 Sep;97(5):847 -56.  
 
8) Mabilleau G, Petrova N, Edmonds ME, Sabokbar A. Number of circulating CD -14 positive cells and 
the serum levels of TNF -Œ± are raised in acute charcot foot. Diabetes Care 2011 Mar;34(3):e33.  
9) Ndip A, Williams A, Jude EB, Serracino -Inglott F, Richardson S, Smyth JV, Boulton AJ, Alexander 
MY.The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic 
Charcot neuroarthropathy. Diabetes. 2011 Aug;60(8):2187 -96 
10) Mabilleau G1, Petrova NL, Edmonds ME, Sabokbar  A. Increased osteoclastic activity in acute 
Charcot's osteoarthropathy: the role of receptor activator of nuclear factor -kappaB ligand. Diabetologia. 
2008 Jun;51(6):1035 -40. 
 
11) Gough A, Abraha H, Li F, Purewal TS, Foster AV, Watkins PJ, Moniz C, Edmonds  ME. 
Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic 
diabetic Charcot neuroarthropathy.Diabet Med. 1997 Jul;14(7):527 -31. 
 
12) Gutekunst DJ, Smith KE, Commean PK, Bohnert KL, Prior FW, Sinacore DR. Impact of Charcot 
neuroarthropathy on metatarsal bone mineral density and geometric strength indices. Bone. 2013 
Jan;52(1):407 -13.  
29 13) La Fontaine J1, Shibuya N, Sampson HW, Valderrama P.Trabecular quality and cellular 
characteristics of normal, diabetic, and charc ot bone. J Foot Ankle Surg. 2011 Nov -Dec;50(6):648 -
53. 
14) Jeffcoate, Game, Cavanagh. The role of proinflammatory cytokines in the cause of neuropathic 
osteoarthropathy (acute Charcot foot) in diabetes. The Lancet. 2005 Dec pg 2058 - 2061  
 
15) Malhotra S, Bello E, Kominsky S.Diabetic foot ulcerations: biomechanics, charcot foot, and total 
contact cast.. Semin Vasc Surg. 2012 Jun;25(2):66 -9. 
 
16) Blume PA, Sumpio B, Schmidt B, Donegan R. Charcot Neuroarthropathy of the Foot and Ankle: 
Diagnosis and Managemen t Strategies. Clin Podiatr Med Surg. 2014 Jan;31(1):151 -72. 
 
17) Diabetes Care. 2011 Jul;34(7):1514 -6. The effect of zoledronic acid on the clinical resolution of 
Charcot neuroarthropathy: a pilot randomized controlled trial. Pakarinen TK1, Laine HJ, M√§enp √§√§ H, 
Mattila P, Lahtela J.  
 
18) Jude EB1, Selby PL, Burgess J, Lilleystone P, Mawer  EB, Page SR, Donohoe M, Foster AV, 
Edmonds ME, Boulton AJ. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double -
blind randomised controlled trial. Diabetologia. 2001 Nov;44(11):2032 -7. 
 
19) Feldmann M, Maini RN. TNF -alpha antibodies and osteoprotegerin decrease systemic bone loss  
associated with inflammation through distinct mechanisms in collagen -induced arthritis. Bone. 2004  
Nov;35(5):1200 -7. 
 
20) Mascarenhas JV, Jude EB. Pathogenesis and medical management of diabetic Charcot 
neuroar thropathy. Med Clin North Am. 2013 Sep;97(5):857 -72. 
 
21) McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low 
bone mineral density. N Engl J Med. 2006;354(8):821 ‚Äì831.  
 
22) Sidlauskas KM, Sutton EE, Biddle MA.Osteoporosis i n men: epidemiology and treatment with 
denosumab. Clin Interv Aging. 2014 Apr 8;9:593 -601. 
 
23) Kumagai Y, Hasunuma T, Padhi D. A randomized, double -blind, placebo -controlled, single -dose 
study to evaluate the safety, tolerability, pharmacokinetics and pha rmacodynamics of denosumab 
administered subcutaneously to postmenopausal Japanese women. Bone. 2011;49(5): 1101 ‚Äì1107.  
 
24) Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in 
postmenopausal women with osteoporosis. N Eng l J Med. 2009;361(8):756 ‚Äì765.  
 
25) Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a 
targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical 
data. Clin Ther. 2012 Mar;34(3): 521-36. 
30  
26) Freemantle N, Satram -Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab 
Adherence Preference Satisfaction) study: a 24 -month, randomized, crossover comparison with 
alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317 ‚Äì326.  
 
27) Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of 
action and effects. Bone. 2011 Apr 1;48(4):677 -92. 
 
28) Sandrow RE, Torg JS, Lapayowker MS, Resnick EJ. The use of thermography in the early 
diagnosis of neur opathic arthropathy in the feet of diabetics. Clin Orthop Relat Res. 1972;88:31 -3.  
 
29) Armstrong DG , Lavery LA, Liswood PJ, Todd WF, Tredwell JA. Infrared dermal thermometry for 
the high -risk diabetic foot. Phys Ther. 1997 Feb;77(2):169 -75. 
 
30) Anderson JJ , Woelffer KE, Holtzman JJ, Jacobs AM. Bisphosphonat es for the treatment of 
Charcot neuroarthropathy. J Foot Ankle Surg. 2004 Sep -Oct;43(5):285 -9. 
 
31) Bem R, Jirkovsk√° A, Fejfarov√° V, Skibov√° J, Jude EB.Intranasal calcitonin in the treatment of  
acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care. 2006 
Jun;29(6):1392 -4. 
 
32) Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM, Manto A, Caradonna P, Ghirlanda G. 
Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled 
trial. Diabetes Care. 2005 May;28(5):1214 -5.  
 
33) Armstrong DG, Lavery LA. Monitoring healing of acute Charcot's arthropathy with infrared 
dermal thermometry. J Rehabil Res Dev. 1997 Jul;34(3):317 -21. 
 
34) Armstro ng DG, Todd WF, Lavery LA, Harkless LB, Bushman TR. The natural history of acute 
Charcot's arthropathy in a diabetic foot specialty clinic. J Am Podiatr Med Assoc. 1997 
Jun;87(6):272 -8. 
 
35) Game FL, Catlow  R, Jones GR, Edmonds ME, Jude EB, Rayman G, Jeffcoate WJ. Audit of 
acute Charcot's disease in the UK: the CDUK study. Diabetologia. 2012 Jan;55(1):32 -5. 
 
36) U.S. Food and Drug Administration: Clinical Trials and Human Subject Protection. (2014, 
September  26) Retrieved from   
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm  
 
 
 